Edition:
India

Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema


Thursday, 15 Mar 2018 

March 15 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA.BIOCRYST PHARMACEUTICALS INC SEES REPORTING TOP-LINE RESULTS FROM APEX-2 PHASE 3 TRIAL IN FIRST HALF OF 2019. 

Company Quote

2.86
 --
20 Sep 2019